COVID-19: mRNA vaccines require two doses for population-scale immunity

New IGC research published in Nature Communications provides highly relevant data regarding COVID-19 immunity in hospital care workers and nursing home residents in response to the Pfizer/BioNTech vaccine.

The study shows that immune responses after a single dose of the vaccine are strikingly heterogeneous among individuals and weaker in older people. The second dose, however, normalizes the presence of IgG antibodies targeting the SARS-CoV-2 spike protein in all ages.

The findings, obtained within the scope of the INFO-VAC project coordinated by Jocelyne Demengeot and Carlos Penha-Gonçalves, indicate that two doses of mRNA vaccines are required to reach population-scale immunity and that the interval between their administration should not be extended. The study also highlights the importance of serological monitoring after vaccination, namely in elderly and immunosuppressed individuals.

 

Read Paper
Updated on 07 february 2022

Cookies settings

Cookies Selection

The Calouste Gulbenkian Foundation uses cookies to improve your browsing experience, security, and its website performance. The Foundation may also use cookies to share information on social media and to display messages and advertisements personalised to your interests, both on our website and in others.